阿帕替尼联合化疗治疗经一线以上化疗后进展的晚期恶性肿瘤的临床研究  

Clinical research on apatinib combined with chemotherapy in treatment of progressive advanced malignant tumor after first-line chemotherapy

作　　者：王娜[1] 谢骥[1,2] 王涛[1] 周亚丽 周思妤 赵倩格 赵昌波 李婷[2] 张燕平 王婷[2] 宋飞雪[1] WANG Na;XIE Ji;WANG Tao;ZHOU Yali;ZHOU Siyu;ZHAO Qian’ge;ZHAO Changbo;LI Ting;ZHANG Yanping;WANG Ting;SONG Feixue(Department of Oncology,Lanzhou University Second Hospital,Lanzhou 730000,Gansu,China;Second School of Clinical Medicine,Lanzhou University,Lanzhou 730000,Gansu,China)

机构地区：[1]兰州大学第二医院肿瘤内科,兰州730000 [2]兰州大学第二临床医学院,兰州730000

出　　处：《癌症进展》2021年第12期1242-1245,共4页Oncology Progress

基　　金：兰州大学第二临床医学院“萃英学子科研培育计划”(CYXZ2020-28)。

摘　　要：目的探讨阿帕替尼联合化疗治疗经一线以上化疗后进展的晚期恶性肿瘤的疗效及安全性。方法选取经一线以上化疗后进展的晚期恶性肿瘤患者100例,包括胃癌、肺癌、肝癌、骨肉瘤、卵巢癌、乳腺癌、结直肠癌及胰腺癌患者。采用随机数字表法将患者分为研究组(n=47,采用阿帕替尼联合化疗)和对照组(n=53,采用单纯化疗),比较两组患者的临床疗效及不良反应发生情况。结果研究组患者的客观缓解率(ORR)为14.9%(7/47),与对照组患者的3.8%(2/53)比较,差异无统计学意义(P﹥0.05);研究组患者的疾病控制率(DCR)为74.5%(35/47),明显高于对照组患者的41.5%(22/53),差异有统计学意义(P﹤0.01)。两组患者乏力/纳差、凝血异常、手足综合征、蛋白尿、白细胞减少的发生率比较,差异均无统计学意义(P﹥0.05);研究组患者高血压的发生率为17.0%(8/47),明显高于对照组的0%(0/53)(P﹤0.01)。两组患者的不良反应大多为1~2级,且可耐受。结论阿帕替尼联合化疗治疗经一线以上化疗后进展的晚期恶性肿瘤具有较好的临床疗效,且其安全性较好,可为临床治疗带来指导意义。Objective To explore the efficacy and safety of apatinib combined with chemotherapy in treatment of progressive advanced malignant tumor after first-line chemotherapy.Method 100 progressive patients with advanced malignant tumor(including patients with gastric cancer,lung cancer,liver cancer,osteosarcoma,ovarian cancer,breast cancer,colorectal cancer and pancreatic cancer)after first-line chemotherapy were enrolled and randomly divided into the study group(n=49,treated with apatinib combined chemotherapy)and the control group(n=53,treated with chemotherapy only),the clinical efficacy and adverse reactions were compared between the two groups.Result The objective response rate(ORR)of the study group and the control group were 14.9%(7/47)and 3.8%(2/53),respectively,the difference was not statistically significant(P>0.05).The disease control rate(DCR)of the study group was 74.5%(35/47),which was higher than 41.5%(22/53)of the control group(P<0.01).There was no significant difference for the incidence of fatigue/anorexia,abnormal blood coagulation,hand-foot syndrome,proteinuria and leukopenia(P>0.05);the incidence of hypertension in the study group was 17.0%(8/47),which was significantly higher than 0%(0/53)in the control group(P<0.01).Most adverse reactions were in tolerable 1-2 grades.Conclusion Apatinib combined with chemotherapy is effective in the treatment of progressive advanced malignant tumor after first-line chemotherapy with better safety,which can provide guidance for clinical treatment.

关 键 词：阿帕替尼 化疗 晚期 恶性肿瘤 

分 类 号：R730[医药卫生—肿瘤]